Comparison of semiquantitative fluorescence imaging and PET tracer uptake in mesothelioma models as a monitoring system for growth and therapeutic effects

Nuclear Medicine and Biology

Volumn 35, Issue 8, 2008, Pages 851-860

  Saito, Yuriko ^a,c   Furukawa, Takako ^a,b   Arano, Yasushi ^c   Fujibayashi, Yasuhisa ^a,b   Saga, Tsuneo ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

FLT; Fluorescence imaging; Mesothelioma; Mouse tumor model; PET

Indexed keywords

2 FLUORO 2 DEOXY DEXTRO GLUCOSE C 14; 3' DEOXY 3' FLUOROTHYMIDINE H 3; CYCLOHEXIMIDE; DACTINOMYCIN; PEMETREXED; RED FLUORESCENT PROTEIN; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG UPTAKE; FLUORESCENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMAGING SYSTEM; ISOTOPE LABELING; MESOTHELIOMA; MONITORING; MOUSE; NONHUMAN; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; FLUORESCENCE; GLUTAMATES; GUANINE; HUMANS; MESOTHELIOMA; MICE; MICE, INBRED BALB C; POSITRON-EMISSION TOMOGRAPHY; TRITIUM;

EID: 56249136525     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.08.002     Document Type: Article

References (28)

1. Hazarika M., White Jr. R.M., Booth B.P., Wang Y.C., Ham D.Y., Liang C.Y., et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11 (2005) 982-992
2. Ramos-Nino M.E., Testa J.R., Altomare D.A., Pass H.I., Carbone M., Bocchetta M., et al. Cellular and molecular parameters of mesothelioma. J Cell Biochem 98 (2006) 723-734
3. Robledo R., and Mossman B. Cellular and molecular mechanisms of asbestos-induced fibrosis. J Cell Physiol 180 (1999) 158-166
4. Kumar P., and Kratzke R.A. Molecular prognostic markers in malignant mesothelioma. Lung Cancer 49 Suppl 1 (2005) S53-S60
5. McVeigh E.R. Emerging imaging techniques. Circ Res 98 (2006) 879-886
6. Blasberg R.G., and Tjuvajev J.G. Molecular-genetic imaging: current and future perspectives. J Clin Invest 111 (2003) 1620-1629
7. Shaner N.C., Campbell R.E., Steinbach P.A., Giepmans B.N., Palmer A.E., and Tsien R.Y. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 22 (2004) 1567-1572
8. Altomare D.A., Vaslet C.A., Skele K.L., De Rienzo A., Devarajan K., Jhanwar S.C., et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 65 (2005) 8090-8095
9. Craighead J.E., Akley N.J., Gould L.B., and Libbus B.L. Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats. Am J Pathol 129 (1987) 448-462
10. Robinson C., van Bruggen I., Segal A., Dunham M., Sherwood A., Koentgen F., et al. A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res 66 (2006) 10786-10794
11. Kane A.B. Animal models of malignant mesothelioma. Inhal Toxicol 18 (2006) 1001-1004
12. Deroose C.M., De A., Loening A.M., Chow P.L., Ray P., Chatziioannou A.F., et al. Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and bioluminescence imaging. J Nucl Med 48 (2007) 295-303
13. Kline R.P., Wu E.X., Petrylak D.P., Szabolcs M., Alderson P.O., Weisfeldt M.L., et al. Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging. Clin Cancer Res 6 (2000) 2146-2156
14. Cullinane C., Dorow D.S., Kansara M., Conus N., Binns D., Hicks R.J., et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 65 (2005) 9633-9636
15. Waldherr C., Mellinghoff I.K., Tran C., Halpern B.S., Rozengurt N., Safaei A., et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med 46 (2005) 114-120
16. Kim T.J., Ravoori M., Landen C.N., Kamat A.A., Han L.Y., Lu C., et al. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 67 (2007) 9337-9345
17. Krohn K.A., Mankoff D.A., Muzi M., Link J.M., and Spence A.M. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 32 (2005) 663-671
18. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 29 (2002) 281-287
19. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 29 (2002) 1462-1469
20. Ramirez J.M., Ocio E.M., San Miguel J.F., and Pandiella A. Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. Leukemia 21 (2007) 797-804
21. Kawai H., Toyohara J., Kado H., Nakagawa T., Takamatsu S., Furukawa T., et al. Acquisition of resistance to antitumor alkylating agent ACNU: a possible target of positron emission tomography monitoring. Nucl Med Biol 33 (2006) 29-35
22. Yau K., Price P., Pillai R.G., and Aboagye E. Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors. Eur J Nucl Med Mol Imaging 33 (2006) 981-987
23. Janne P.A., Taffaro M.L., Salgia R., and Johnson B.E. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 62 (2002) 5242-5247
24. Vogelzang N.J., Porta C., and Mutti L. New agents in the management of advanced mesothelioma. Semin Oncol 32 (2005) 336-350
25. Yang H., Bocchetta M., Kroczynska B., Elmishad A.G., Chen Y., Liu Z., et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A 103 (2006) 10397-10402
26. 18F]fluoro-3′-deoxythymidine (FLT). Mol Imaging Biol 9 (2007) 340-347
27. 18F]FLT. Eur J Nucl Med Mol Imaging 34 (2007) 1775-1782
28. Monazzam A., Josephsson R., Blomqvist C., Carlsson J., Langstrom B., and Bergstrom M. Application of the multicellular tumours pheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer. Breast Cancer Res 9 (2007) R45